Literature DB >> 16401284

Counterfactual links to the proportion of treatment effect explained by a surrogate marker.

Jeremy M G Taylor1, Yue Wang, Rodolphe Thiébaut.   

Abstract

In a randomized clinical trial, a statistic that measures the proportion of treatment effect on the primary clinical outcome that is explained by the treatment effect on a surrogate outcome is a useful concept. We investigate whether a statistic proposed to estimate this proportion can be given a causal interpretation as defined by models of counterfactual variables. For the situation of binary surrogate and outcome variables, two counterfactual models are considered, both of which include the concept of the proportion of the treatment effect, which acts through the surrogate. In general, the statistic does not equal either of the two proportions from the counterfactual models, and can be substantially different. Conditions are given for which the statistic does equal the counterfactual model proportions. A randomized clinical trial with potential surrogate endpoints is undertaken in a scientific context; this context will naturally place constraints on the parameters of the counterfactual model. We conducted a simulation experiment to investigate what impact these constraints had on the relationship between the proportion explained (PE) statistic and the counterfactual model proportions. We found that observable constraints had very little impact on the agreement between the statistic and the counterfactual model proportions, whereas unobservable constraints could lead to more agreement.

Mesh:

Substances:

Year:  2005        PMID: 16401284     DOI: 10.1111/j.1541-0420.2005.00380.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  27 in total

1.  Comparing biomarkers as principal surrogate endpoints.

Authors:  Ying Huang; Peter B Gilbert
Journal:  Biometrics       Date:  2011-04-22       Impact factor: 2.571

2.  Are brain volumes based on magnetic resonance imaging mediators of the associations of cumulative lead dose with cognitive function?

Authors:  Brian Caffo; Sining Chen; Walter Stewart; Karen Bolla; David Yousem; Christos Davatzikos; Brian S Schwartz
Journal:  Am J Epidemiol       Date:  2007-12-12       Impact factor: 4.897

3.  Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy.

Authors:  Erin E Gabriel; Peter B Gilbert
Journal:  Biostatistics       Date:  2013-12-13       Impact factor: 5.899

4.  A causal framework for surrogate endpoints with semi-competing risks data.

Authors:  Debashis Ghosh
Journal:  Stat Probab Lett       Date:  2012-06-16       Impact factor: 0.870

5.  Bayesian inference for causal mediation effects using principal stratification with dichotomous mediators and outcomes.

Authors:  Michael R Elliott; Trivellore E Raghunathan; Yun Li
Journal:  Biostatistics       Date:  2010-01-25       Impact factor: 5.899

6.  Evaluating candidate principal surrogate endpoints.

Authors:  Peter B Gilbert; Michael G Hudgens
Journal:  Biometrics       Date:  2008-03-24       Impact factor: 2.571

7.  Evaluation of longitudinal surrogate markers.

Authors:  Denis Agniel; Layla Parast
Journal:  Biometrics       Date:  2020-06-22       Impact factor: 2.571

8.  Surrogate markers for time-varying treatments and outcomes.

Authors:  Jesse Y Hsu; Edward H Kennedy; Jason A Roy; Alisa J Stephens-Shields; Dylan S Small; Marshall M Joffe
Journal:  Clin Trials       Date:  2015-05-06       Impact factor: 2.486

9.  Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition.

Authors:  Peter B Gilbert; Erin E Gabriel; Ying Huang; Ivan S F Chan
Journal:  J Causal Inference       Date:  2015-02-01

10.  Intermediacy and gene-environment interaction: the example of CHRNA5-A3 region, smoking, nicotine dependence, and lung cancer.

Authors:  Sholom Wacholder; Nilanjan Chatterjee; Neil Caporaso
Journal:  J Natl Cancer Inst       Date:  2008-10-28       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.